<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90407</article-id><article-id pub-id-type="doi">10.7554/eLife.90407</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Tuberculosis Vaccine</subject></subj-group></article-categories><title-group><article-title>Dual delivery of antigens shows promise</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-326091"><name><surname>Luque-García</surname><given-names>Jose L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6273-0349</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Jose L Luque-García</bold> is in the Department of Analytical Chemistry, School of Chemistry, Universidad Complutense of Madrid, Madrid, Spain</p></bio></contrib><contrib contrib-type="author" corresp="yes" id="author-52621"><name><surname>Prados-Rosales</surname><given-names>Rafael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5964-0166</contrib-id><email>rafael.prados@uam.es</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Rafael Prados-Rosales</bold> in the Department of Preventive Medicine, Public Health and Microbiology, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02p0gd045</institution-id><institution>Department of Analytical Chemistry, School of Chemistry, Universidad Complutense of Madrid</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cby8j38</institution-id><institution>Department of Preventive Medicine, Public Health and Microbiology, School of Medicine, Universidad Autonoma de Madrid</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e90407</elocation-id><permissions><copyright-statement>© 2023, Luque-García and Prados-Rosales</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Luque-García and Prados-Rosales</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90407-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.87431" id="ra1"/><abstract><p>The simultaneous delivery of protein and lipid antigens via nanoparticles may help efforts to develop a new vaccine for tuberculosis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>tuberculosis</kwd><kwd>vaccines</kwd><kwd>mycolic acids</kwd><kwd>T cells</kwd><kwd>mycobacterial antigens</kwd><kwd>Mycobacterium tuberculosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The simultaneous delivery of protein and lipid antigens via nanoparticles may help efforts to develop a new vaccine for tuberculosis.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Morgun E, Zhu J, Almunif S, Bobbala S, Aguilar MS, Wang J, Conner K, Cui Y, Cao L, Seshadri C, Scott EA, Wang C. 2023. Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells. <italic>eLife</italic> <bold>12</bold>:RP87431. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.87431">10.7554/eLife.87431</ext-link>.</p></boxed-text><p>The BCG vaccine was first used in 1921 and, remarkably, over 100 years later it is the only licensed vaccine for use against tuberculosis. While the BCG vaccine provides protection against tuberculosis that has spread beyond the lungs in young children, its efficacy against lung infections in adults – the main form of the disease – is variable (<xref ref-type="bibr" rid="bib8">Trunz et al., 2006</xref>). Tuberculosis is caused by a bacterium called <italic>Mycobacterium tuberculosis</italic> (<italic>M. tb</italic>), and one reason for the lack of more effective vaccines is that we still do not know which <italic>M. tb</italic> antigens are able to induce protective immunity (<xref ref-type="bibr" rid="bib4">Guinn and Rubin, 2017</xref>).</p><p>Almost 20 vaccine candidates are currently being evaluated in clinical trials. Most of these aim to induce a response from immune cells called type 1 helper T cells by exposing them to protein antigens from <italic>M. tb</italic>, although other approaches are also being explored. Now, in eLife, Evan Scott and Chyung-Ru Wang from Northwestern University and colleagues – including Eva Morgun as first author – report a new approach that involves using protein antigens and long-chain fatty acids called mycolic acids, found in the <italic>M. tb</italic> cell envelope, to induce an immune response (<xref ref-type="bibr" rid="bib6">Morgun et al., 2023</xref>).</p><p>Previous studies have shown that the immune system generates a protective response when exposed to mycolic acids: this response is mediated by a subset of “unconventional” T cells, but the details of the response are not fully understood (<xref ref-type="bibr" rid="bib7">Shang et al., 2018</xref>; <xref ref-type="bibr" rid="bib9">Zhao et al., 2015</xref>). Moreover, there have been very few attempts to explore the use of mycolic acids as alternative antigens for a tuberculosis vaccine, partly because most vaccine delivery systems are designed for hydrophilic cargoes (such as proteins), whereas mycolic acids are hydrophobic. Morgun et al. have overcome this problem by developing a system that can deliver hydrophobic and hydrophilic cargoes at the same time.</p><p>Building upon evidence that vaccine formulations including <italic>M. tb</italic> lipids encapsulated in liposomes – hollow spherical structures made of lipid bilayers – provide protection (<xref ref-type="bibr" rid="bib3">Dascher et al., 2003</xref>; <xref ref-type="bibr" rid="bib5">Larrouy-Maumus et al., 2017</xref>), Morgun et al. developed structures called bicontinuous nanospheres. These self-assembled polymer-based structures can carry both hydrophobic and hydrophilic components because they possess an organized internal cubic structure including hydrophobic bilayers and hydrophilic aqueous channels (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Furthermore, the nanospheres retain antigens more efficiently than other lipid nanostructures, and only release their contents when they reach the target compartment within antigen-presenting cells. These features increase the persistence of the antigens within cells and stimulate the immune system for longer periods of time, which leads to a more robust immune response (<xref ref-type="bibr" rid="bib2">Correia-Pinto et al., 2013</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Bicontinuous nanospheres can be loaded with both protein and lipid antigens.</title><p>Structure of a bicontinuous nanosphere. Hydrophilic (blue) regions contain protein antigens and hydrophobic (green) regions contain mycolic acids, represented by tentative structures. Figure based on image from <xref ref-type="bibr" rid="bib1">Allen et al., 2018</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90407-fig1-v1.tif"/></fig><p>Morgun et al. used a mouse model that allowed them to observe the immune response to dual vaccination with mycolic acids and proteins. This showed that T cells responded to both antigens: however, only mycolic acid remained detectable inside immune cells after vaccination. It remains unclear if this differential antigen persistence is due to the nanosphere delivery system, the protein itself, or a distinct mechanism of antigen capture and maintenance by immune cells.</p><p>It is worth noting that the persistence of mycolic acids likely occurs during in vivo infection and, therefore, the dual vaccination strategy may mimic a previously overlooked feature of the infection process. Supporting this notion, Morgun et al. found that vaccination with an attenuated <italic>M. tb</italic> strain resulted in a persistence of mycolic acids similar to that observed with the dual approach. These results suggest that vaccines using live attenuated strains of <italic>M. tb</italic> likely provide protection via mycolic acid-specific T cells. This raises the question of whether the persistence of lipid antigens is a key aspect of the protective immune response: this is something that needs to be considered when developing tuberculosis vaccines in the future.</p><p>Although definitive proof of protective immunity induced by dual-loaded bicontinuous nanospheres remains elusive, this approach allowing combinations of antigens – both hydrophobic and hydrophilic – can be used as an alternative strategy to live attenuated vaccines. Moreover, the ability to test combinations of alternative antigens will aid the development of vaccines for tuberculosis more generally. Future work with this system could also investigate the role of lipid persistence in other overlooked aspects of tuberculosis immunity, such as antibody responses, which might have an important contribution to protective immunity.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>SD</given-names></name><name><surname>Bobbala</surname><given-names>S</given-names></name><name><surname>Karabin</surname><given-names>NB</given-names></name><name><surname>Modak</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Benchmarking bicontinuous nanospheres against polymersomes for in vivo biodistribution and dual intracellular delivery of lipophilic and water-soluble payloads</article-title><source>ACS Applied Materials &amp; Interfaces</source><volume>10</volume><fpage>33857</fpage><lpage>33866</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b09906</pub-id><pub-id pub-id-type="pmid">30213189</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia-Pinto</surname><given-names>JF</given-names></name><name><surname>Csaba</surname><given-names>N</given-names></name><name><surname>Alonso</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Vaccine delivery carriers: insights and future perspectives</article-title><source>International Journal of Pharmaceutics</source><volume>440</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.04.047</pub-id><pub-id pub-id-type="pmid">22561794</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dascher</surname><given-names>CC</given-names></name><name><surname>Hiromatsu</surname><given-names>K</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Morehouse</surname><given-names>C</given-names></name><name><surname>Watts</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>McMurray</surname><given-names>DN</given-names></name><name><surname>LeClair</surname><given-names>KP</given-names></name><name><surname>Porcelli</surname><given-names>SA</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis</article-title><source>International Immunology</source><volume>15</volume><fpage>915</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxg091</pub-id><pub-id pub-id-type="pmid">12882829</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinn</surname><given-names>KM</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tuberculosis: Just the FAQs</article-title><source>mBio</source><volume>8</volume><elocation-id>e01910-17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01910-17</pub-id><pub-id pub-id-type="pmid">29259086</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrouy-Maumus</surname><given-names>G</given-names></name><name><surname>Layre</surname><given-names>E</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Prandi</surname><given-names>J</given-names></name><name><surname>Rayner</surname><given-names>E</given-names></name><name><surname>Lepore</surname><given-names>M</given-names></name><name><surname>de Libero</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Puzo</surname><given-names>G</given-names></name><name><surname>Gilleron</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis</article-title><source>Vaccine</source><volume>35</volume><fpage>1395</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.01.079</pub-id><pub-id pub-id-type="pmid">28190740</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgun</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Almunif</surname><given-names>S</given-names></name><name><surname>Bobbala</surname><given-names>S</given-names></name><name><surname>Aguilar</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Conner</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Seshadri</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>EA</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells</article-title><source>eLife</source><volume>12</volume><elocation-id>RP87431</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.87431.1</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Kats</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Morgun</surname><given-names>E</given-names></name><name><surname>Velluto</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>C-R</given-names></name><name><surname>Scott</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of <italic>Mycobacterium tuberculosis</italic> lipid-specific T cell responses by pulmonary delivery of mycolic acid-loaded polymeric micellar nanocarriers</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2709</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02709</pub-id><pub-id pub-id-type="pmid">30538700</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trunz</surname><given-names>BB</given-names></name><name><surname>Fine</surname><given-names>P</given-names></name><name><surname>Dye</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness</article-title><source>Lancet</source><volume>367</volume><fpage>1173</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68507-3</pub-id><pub-id pub-id-type="pmid">16616560</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Bagchi</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C-R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mycolic acid-specific T cells protect against <italic>Mycobacterium tuberculosis</italic> infection in a humanized transgenic mouse model</article-title><source>eLife</source><volume>4</volume><elocation-id>e08525</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.08525</pub-id><pub-id pub-id-type="pmid">26652001</pub-id></element-citation></ref></ref-list></back></article>